AC Immune S.A. (ACIU)

$3.54 +0.06 (1.72%)
Market Cap 349.43M
Revenue (ttm) 31.02M
Net Income (ttm) -57.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -186.46%
Debt to Equity Ratio 0.00
Volume 253,900
Avg Vol 790,636
Day's Range N/A - N/A
Shares Out 100.41M
Stochastic %K 45%
Beta 1.62
Analysts Strong Sell
Price Target $9.67

Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, confor...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 21 345 91 21
Fax: 41 21 345 91 20
Address:
Building B, EPFL Innovation Park, Lausanne, Switzerland
Meltingflame
Meltingflame Jan. 25 at 10:26 PM
$ACIU I am slowly building up position here after considerable studies the past few days. In summary: To have 500x higher levels in the CSF compared to placebo is effectively unheard of in this field. It suggests they have solved the "delivery problem" that plagues passive antibodies. If the drug fails now, it won't be because it didn't get to the crime scene; it will be because the mechanism itself is flawed (which the NfL data suggests is unlikely). In addition, the clinical and scientific board they assembled essentially wrote the clinical trials book, which I should imagine ensures they don’t make the same mistakes that Roche did. I am at only 3K shares now. My target is to slowly walk it up to 10K. Hopefully the bus doesn’t leave the station by the time I get there. ☺️ Reasonably BULLISH!!
0 · Reply
BLD33
BLD33 Jan. 23 at 7:56 PM
$MRNA nice move January $ACIU ready to Breakout 4 soon. Last time from 4 to 10 in two sesions
0 · Reply
midas7576
midas7576 Jan. 23 at 6:16 PM
$ACIU mRNA-based Therapeutics Summit Europe (Berlin, Germany): January 27–29, 2026.
0 · Reply
Trip1801
Trip1801 Jan. 23 at 5:31 PM
$ACIU is so ready for a breakout >$5. Strong pipeline, strong partners, well financed. Just a question of time.
0 · Reply
midas7576
midas7576 Jan. 23 at 5:15 PM
$ACIU
0 · Reply
midas7576
midas7576 Jan. 22 at 1:09 PM
$ACIU Trial Updated: https://clinicaltrials.gov/study/NCT05651516?term=PI-2620&rank=7
0 · Reply
lit5644
lit5644 Jan. 15 at 4:14 PM
$ACIU Nice, unusual volume here. $16 price targets still in place.
0 · Reply
Brett1223
Brett1223 Jan. 15 at 12:33 AM
$ACIU they are not presenting. Something cooking
0 · Reply
midas7576
midas7576 Jan. 14 at 6:06 PM
$ACIU Now not believed to be presenting at JPM Conference this week. Something up?
1 · Reply
midas7576
midas7576 Jan. 14 at 11:44 AM
$ACIU https://ir.acimmune.com/static-files/c417692c-14b5-43d1-944f-19149ee7e849
0 · Reply
Latest News on ACIU
AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD

Dec 15, 2025, 2:50 PM EST - 6 weeks ago

AC Immune: Maintaining 'Buy' Rating On Next Steps For ACI-7104.056 Development In PD

AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's

Dec 11, 2025, 12:47 PM EST - 6 weeks ago

AC Immune Trial Shows Early Signs Immunotherapy May Slow Parkinson's

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease

Dec 11, 2025, 7:00 AM EST - 6 weeks ago

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson's Disease

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Nov 4, 2025, 7:00 AM EST - 3 months ago

AC Immune Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine

Oct 24, 2025, 8:50 AM EDT - 3 months ago

First Characterization of a TDP-43 PET Tracer Published in Nature Communications Showing Potential of AC Immune's ACI-19626 in Precision Medicine

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 5, 2025, 7:00 AM EDT - 6 months ago

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 30, 2025, 7:00 AM EDT - 9 months ago

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease

Apr 2, 2025, 6:00 AM EDT - 10 months ago

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

Mar 25, 2025, 7:00 AM EDT - 11 months ago

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

Mar 13, 2025, 7:00 AM EDT - 11 months ago

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients

Nov 14, 2024, 10:32 AM EST - 1 year ago

AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

Jul 31, 2024, 8:30 AM EDT - 1 year ago

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

Jul 26, 2024, 3:10 PM EDT - 1 year ago

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease

Jul 25, 2024, 7:00 AM EDT - 1 year ago

AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024

May 28, 2024, 7:00 AM EDT - 1 year ago

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024

Alzheimer's vaccine licensing deal boosts AC Immune

May 13, 2024, 8:47 AM EDT - 1 year ago

Alzheimer's vaccine licensing deal boosts AC Immune

AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 13, 2024, 6:05 AM EDT - 1 year ago

AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease

May 13, 2024, 6:00 AM EDT - 1 year ago

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease

TAK

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

Mar 14, 2024, 7:00 AM EDT - 2 years ago

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

Feb 22, 2024, 7:00 AM EST - 2 years ago

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

Jan 22, 2024, 7:00 AM EST - 2 years ago

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases

Jan 3, 2024, 8:10 AM EST - 2 years ago

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases

AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts

Dec 18, 2023, 6:25 PM EST - 2 years ago

AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts

AC Immune Announces Pricing of Underwritten Offering of Common Shares

Dec 15, 2023, 7:56 AM EST - 2 years ago

AC Immune Announces Pricing of Underwritten Offering of Common Shares

AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial

Dec 15, 2023, 7:22 AM EST - 2 years ago

AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

Dec 1, 2023, 7:00 AM EST - 2 years ago

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

AC Immune to Present at the Jefferies 2023 London Healthcare Conference

Nov 7, 2023, 7:00 AM EST - 2 years ago

AC Immune to Present at the Jefferies 2023 London Healthcare Conference

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Nov 3, 2023, 7:00 AM EDT - 2 years ago

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023

Nov 2, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023

AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic

Oct 27, 2023, 7:00 AM EDT - 2 years ago

AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference

Oct 17, 2023, 7:00 AM EDT - 2 years ago

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023

Oct 5, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

Sep 5, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Aug 4, 2023, 7:00 AM EDT - 2 years ago

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023

Jul 28, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023

AC Immune SA Appoints New Chief Medical Officer

Jul 26, 2023, 7:00 AM EDT - 2 years ago

AC Immune SA Appoints New Chief Medical Officer

AC Immune Showcasing Precision Medicine Programs at AAIC 2023

Jul 3, 2023, 7:00 AM EDT - 2 years ago

AC Immune Showcasing Precision Medicine Programs at AAIC 2023

AC Immune's stock soars 13% after FDA grants fast-track designation to Alzheimer's treatment

Jun 27, 2023, 7:52 AM EDT - 2 years ago

AC Immune's stock soars 13% after FDA grants fast-track designation to Alzheimer's treatment

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer's Disease

Jun 27, 2023, 7:00 AM EDT - 2 years ago

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer's Disease

AC Immune Holds Annual General Meeting of Shareholders

Jun 23, 2023, 4:30 PM EDT - 2 years ago

AC Immune Holds Annual General Meeting of Shareholders

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Apr 28, 2023, 7:00 AM EDT - 2 years ago

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update

AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer's Disease

Apr 5, 2023, 7:00 AM EDT - 3 years ago

AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer's Disease

AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

Mar 20, 2023, 8:00 AM EDT - 3 years ago

AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

AC Immune: Dementia-Focused Swiss Biotech With A Sad History Of Failures

Mar 18, 2023, 9:00 AM EDT - 3 years ago

AC Immune: Dementia-Focused Swiss Biotech With A Sad History Of Failures

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 16, 2023, 7:00 AM EDT - 3 years ago

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023

Mar 8, 2023, 7:00 AM EST - 3 years ago

AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

Feb 7, 2023, 7:00 AM EST - 3 years ago

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

AC Immune to Present at the SVB Securities Global Biopharma Conference

Feb 2, 2023, 8:15 AM EST - 3 years ago

AC Immune to Present at the SVB Securities Global Biopharma Conference

AC Immune's ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer's Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

Jan 26, 2023, 7:00 AM EST - 3 years ago

AC Immune's ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer's Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer's Disease

Jan 18, 2023, 7:00 AM EST - 3 years ago

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer's Disease

Meltingflame
Meltingflame Jan. 25 at 10:26 PM
$ACIU I am slowly building up position here after considerable studies the past few days. In summary: To have 500x higher levels in the CSF compared to placebo is effectively unheard of in this field. It suggests they have solved the "delivery problem" that plagues passive antibodies. If the drug fails now, it won't be because it didn't get to the crime scene; it will be because the mechanism itself is flawed (which the NfL data suggests is unlikely). In addition, the clinical and scientific board they assembled essentially wrote the clinical trials book, which I should imagine ensures they don’t make the same mistakes that Roche did. I am at only 3K shares now. My target is to slowly walk it up to 10K. Hopefully the bus doesn’t leave the station by the time I get there. ☺️ Reasonably BULLISH!!
0 · Reply
BLD33
BLD33 Jan. 23 at 7:56 PM
$MRNA nice move January $ACIU ready to Breakout 4 soon. Last time from 4 to 10 in two sesions
0 · Reply
midas7576
midas7576 Jan. 23 at 6:16 PM
$ACIU mRNA-based Therapeutics Summit Europe (Berlin, Germany): January 27–29, 2026.
0 · Reply
Trip1801
Trip1801 Jan. 23 at 5:31 PM
$ACIU is so ready for a breakout >$5. Strong pipeline, strong partners, well financed. Just a question of time.
0 · Reply
midas7576
midas7576 Jan. 23 at 5:15 PM
$ACIU
0 · Reply
midas7576
midas7576 Jan. 22 at 1:09 PM
$ACIU Trial Updated: https://clinicaltrials.gov/study/NCT05651516?term=PI-2620&rank=7
0 · Reply
lit5644
lit5644 Jan. 15 at 4:14 PM
$ACIU Nice, unusual volume here. $16 price targets still in place.
0 · Reply
Brett1223
Brett1223 Jan. 15 at 12:33 AM
$ACIU they are not presenting. Something cooking
0 · Reply
midas7576
midas7576 Jan. 14 at 6:06 PM
$ACIU Now not believed to be presenting at JPM Conference this week. Something up?
1 · Reply
midas7576
midas7576 Jan. 14 at 11:44 AM
$ACIU https://ir.acimmune.com/static-files/c417692c-14b5-43d1-944f-19149ee7e849
0 · Reply
DARKP00L
DARKP00L Jan. 13 at 7:34 PM
$ACIU this stock is seeing a surge in interest. Market volatility might ensue!
0 · Reply
lucabrix
lucabrix Jan. 13 at 4:43 PM
$ACIU waiting for 4$ resistance to fall
0 · Reply
lit5644
lit5644 Jan. 13 at 4:31 PM
$ACIU Volume steadily picking up, nice buyout candidate IMO!
0 · Reply
midas7576
midas7576 Jan. 9 at 5:50 PM
$ACIU $7:50 MAY CALLS!
1 · Reply
midas7576
midas7576 Jan. 9 at 8:17 AM
$ACIU AC Immune is presenting at the 44th Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco from January 12-15, 2026. The presentation details are as follows: Date: Thursday, January 15, 2026 Time: 12:00 p.m. local time (Pacific Time) Location: Westin St. Francis Hotel, San Francisco
1 · Reply
deeperfect77
deeperfect77 Jan. 8 at 2:31 AM
$ACIU surprised there's not more eyes on this. Quiet upside creeper
0 · Reply
midas7576
midas7576 Jan. 7 at 2:01 PM
$ACIU Updated today: https://clinicaltrials.gov/study/NCT05641688
0 · Reply
midas7576
midas7576 Jan. 7 at 4:16 AM
$ACIU - Will be the next $VTYX . They actually have a larger pipeline.
0 · Reply
midas7576
midas7576 Jan. 6 at 2:55 PM
$ACIU .
0 · Reply
midas7576
midas7576 Jan. 6 at 2:55 PM
$ACIU
0 · Reply
TheRealBearKillaAlerts
TheRealBearKillaAlerts Jan. 5 at 3:14 PM
$ACIU Bullish on $ACIU! Biotech play with healthcare value focus. Technical setup looks solid. 🚀
0 · Reply
midas7576
midas7576 Jan. 5 at 2:46 PM
$ACIU Paying over the offer for stock today!
0 · Reply